Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass / Plastic Bottles, Pouches / Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    February 2022

  • Pages
    305

  • View Count
    17801

Example Insights

Live-Biotherapeutic-Market-Context-thumb Live-Biotherapeutic-Market-the-rise-thumb Live-Biotherapeutic-Market-basis-thumb Live-Biotherapeutic-Market-Offered-thumb Live-Biotherapeutic-Market-production-thumb
Live-Biotherapeutic-Market-Analysis-thumb Live-Biotherapeutic-Market-Collaborations-thumb Live-Biotherapeutic-Market-Landscape-thumb Live-Biotherapeutic-Market-Players-thumb Live-Biotherapeutic-Market-Developers-thumb
Live-Biotherapeutic-Market-Capacity-thumb Live-Biotherapeutic-Market-growth-thumb Live-Biotherapeutic-Market-Formulation-thumb Live-Biotherapeutic-Market-Geography-thumb  

Overview

I believe that a lot of start-ups have entered the market, however, only a few companies have established their own facilities to manufacture microbiome-based products. This is primarily due to the fact that the cost of establishing an LBP production facility is high, and therefore, requires significant capital investment. As a result, companies have demonstrated preference to outsource manufacturing operations

-Vice President, Sales and Business Development, a US based Small-sized Company

Given the advancement of several promising microbiome-based live biotherapeutic products through clinical pipeline, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years. Specifically, in 2020, around 575 IND applications were filed for such therapies, targeting a myriad of diseases indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders, indicating remarkable scientific progress of these breakthrough drug candidates. It is also worth highlighting that SER-109, a microbiome-based therapy developed by Seres Therapeutics, is expected to receive marketing approval from the US Food and Drug Administration (FDA) in 2022; this is further likely to propel the growth in this domain. Further, over 640 patents focused on microbiome therapeutics were granted approval in the year 2020. In addition, during the same time frame, USD 1.5 billion was invested for the development of microbiome-based therapeutics. Although a lot has been achieved in terms of development of live biotherapeutic products, there are certain challenges associated with the complexity of the process. Other key concerns shared by contemporary innovators include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP) and capacity. 

In order to address the technical and operational challenges outlined above, several microbiome developers prefer to rely on contract manufacturing organizations (CMOs). It is worth highlighting that, currently, over 50 players engaged in the manufacturing of microbiome-related products carry out operations either in-house or on contract basis. The current market landscape of microbiome contract manufacturers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. Moreover, in recent years, several players engaged in this domain have forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings and operate as one-stop-shops. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the microbiome production process, we believe that the microbiome manufacturing market is expected to witness significant growth over the next decade.

Scope of the Report

The “Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass / Plastic Bottles, Pouches / Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035” report features an extensive study on the in- house and contract manufacturing organizations within the microbiome industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:

  • A detailed overview of the overall landscape of companies offering contract manufacturing services for the development of microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. Further, it provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities. 
  • A detailed landscape of the live biotherapeutic products and microbiome manufacturing facilities established across key geographical regions (North America, Europe and Asia-Pacific), highlighting the key manufacturing hubs for microbiomes.  
  • An in-depth company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (in terms of scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.
  • Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics across both clinical and commercial scales of operation. Each profile features a brief overview of the company, details related to its microbiome-related service portfolio, microbiome manufacturing facilities, recent developments, and an informed future outlook.
  • A list of nearly 70 microbiome-focused drug developers that are likely to partner with manufacturers engaged in this domain. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.
  • A review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.
  • An analysis of recent developments within the microbiome manufacturing industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions. 
  • An estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity based on the scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
  • An informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.
  • A qualitative analysis, highlighting various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on their year of establishment, company size and location of headquarters.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the microbiome manufacturing market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include: 

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information. 

Key Questions Answered

  • Who are the key players engaged in offering contract manufacturing services for microbiome therapeutics?
  • What are the key challenges faced by microbiome contract manufacturers?
  • Who are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?
  • What is the annual clinical demand for microbiome-based live biotherapeutics? 
  • What is the current, installed contract manufacturing capacity for live biotherapeutics?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?
  • What are the various initiatives undertaken by big pharma players in this domain? 
  • What percentage of live biotherapeutics manufacturing operations are outsourced to service providers?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to live biotherapeutics manufacturing?
     

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics manufacturing market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the human microbiome project (HMP). Further, the chapter features the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.

Chapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 25 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. It also provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities. 

Chapter 5 provides a detailed landscape of microbiome manufacturing facilities in key regions (North America, Europe and Asia-Pacific). It includes analysis and map representations based on location of these facilities, highlighting key provinces as the manufacturing hubs.

Chapter 6 features an insightful company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.

Chapter 7 includes detailed profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities, and recent developments and an informed future outlook.

Chapter 8 provides list of nearly 70 microbiome-focused drug developers that are anticipated to partner with manufacturers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.

Chapter 9 presents a review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity,  and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.

Chapter 10 presents detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the microbiome manufacturing industry, during the period between 2016 and 2021.

Chapter 11 features an in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions. 

Chapter 12 provides an estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).

Chapter 13 presents an informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.

Chapter 14 provides a qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 15 includes a case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on the year of establishment, company size and location of headquarters.

Chapter 16 presents an insightful market forecast analysis, highlighting the future potential of microbiome manufacturing market till 2035. We have segmented the market on the basis of [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass / plastic bottles, pouches / sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbiome contract manufacturing market, based on the research and analysis described in the previous chapters. 

Chapter 18 is a collection of transcripts of interviews conducted with various stakeholders in the industry. 

Chapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Human Microbiota and Microbiome

3.3. Overview of Gut Flora

3.3.1. Role of Gut Flora in Healthy Individuals
3.3.2. Factors Affecting Human Gut Flora

3.4. The Human Microbiome Project (HMP)

3.5. Overview of Microbiome Therapies
3.5.1. Types of Microbiome Therapies
3.5.1.1. Probiotics
3.5.1.2. Prebiotics

3.5.2. Applications of Microbiome Therapies
3.5.3. Microbiome Therapies Supply Chain

3.6. Microbiome-based Product Manufacturing
3.6.1. Key Steps Involved
3.6.2. Associated Challenges
3.6.3. Role of Contract Manufacturing Organizations (CMOs)
3.6.4. Demand for Contract Manufacturing Services

3.7. Key Considerations while Selecting a Suitable CMO Partner

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Type of Product Manufactured
4.2.6. Analysis by Type of Formulation
4.2.7. Analysis by Scale of Operation and Type of Formulation
4.2.8. Analysis by Type of Primary Packaging Used
4.2.9. Analysis by Type of Formulation and Type of Primary Packaging Used
4.2.10. Analysis by Type of Fermentation
4.2.11. Analysis by Type of Fermentation and Location of Headquarters
4.2.12. Analysis by Type of Service(s) Offered
4.2.13. Analysis by Number of Manufacturing Facilities
4.2.14. Analysis by Location of Manufacturing Facilities

4.3. Live Biotherapeutic Products and Microbiome In-House Manufacturers: Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Scale of Operation
4.3.4. Analysis by Location of Headquarters
4.3.5. Analysis by Location of Manufacturing Facilities

5. REGIONAL CAPABILITY ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in North America
5.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in Europe
5.5. Live Biotherapeutic Products and Microbiome Contract Manufacturing Facilities in Asia-Pacific

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.4. Company Competitiveness: North America
6.5. Company Competitiveness: Europe
6.6. Company Competitiveness: Asia-Pacific
6.7. Capability Benchmarking of Top Microbiome Contract Manufactures

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. CMOs Headquartered in North America
7.2.1. Capsugel
7.2.1.1. Company Overview
7.2.1.2. Service Portfolio
7.2.1.3. Facilities Dedicated to Microbiome Manufacturing
7.2.1.4. Recent Developments and Future Outlook

7.2.2. Jeneil Biotech
7.2.2.1. Company Overview
7.2.2.2. Service Portfolio
7.2.2.3. Facilities Dedicated to Microbiome Manufacturing
7.2.2.4. Recent Developments and Future Outlook

7.2.3. UAS Labs
7.2.3.1. Company Overview
7.2.3.2. Service Portfolio
7.2.3.3. Facilities Dedicated to Microbiome Manufacturing
7.2.3.4. Recent Developments and Future Outlook

7.3. CMOs Headquartered in Europe
7.3.1. Biose
7.3.1.1. Company Overview
7.3.1.2. Service Portfolio
7.3.1.3. Facilities Dedicated to Microbiome Manufacturing
7.3.1.4. Recent Developments and Future Outlook

7.3.2. Cerbios-Pharma
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Service Portfolio
7.3.2.4. Facilities Dedicated to Microbiome Manufacturing
7.3.2.5. Recent Developments and Future Outlook

7.3.3. Inpac Probiotics
7.3.3.1. Company Overview
7.3.3.2. Service Portfolio
7.3.3.3. Facilities Dedicated to Microbiome Manufacturing
7.3.3.4. Recent Developments and Future Outlook

7.3.4. NIZO
7.3.4.1. Company Overview
7.3.4.2. Service Portfolio
7.3.4.3. Facilities Dedicated to Microbiome Manufacturing
7.3.4.4. Recent Developments and Future Outlook

7.3.5 Winclove Probiotics
7.3.5.1. Company Overview
7.3.5.2. Service Portfolio
7.3.5.3. Facilities Dedicated to Microbiome Manufacturing
7.3.5.4. Recent Developments and Future Outlook

7.4. CMOs Headquartered in Asia-Pacific and Rest of the World
7.4.1. BJP Laboratories
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.3. Facilities Dedicated to Microbiome Manufacturing
7.4.1.4. Recent Developments and Future Outlook

8. LIKELY PARTNER ANALYSIS
8.1. Chapter Overview
8.2. Scoring Criteria and Key Assumptions
8.3. Scope and Methodology
8.4. Key Potential Strategic Partners for Live Biotherapeutic Products and Microbiome Manufacturers
8.4.1. Likely Partner Opportunities in North America
8.4.2. Likely Partner Opportunities in Europe
8.4.3. Likely Partner Opportunities in Asia-Pacific

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Microbiome Related Initiatives of Big Pharmaceutical Players
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Phase of Development
9.3.3. Analysis by Type of Therapy
9.3.4. Analysis by Type of Drug Molecule
9.3.5. Analysis by Target Therapeutic Areas

9.4. Benchmark Analysis of Big Pharmaceutical Players
9.4.1. Spider Web Analysis: AbbVie
9.4.2. Spider Web Analysis: AstraZeneca
9.4.3. Spider Web Analysis: Bristol-Myers Squibb
9.4.4. Spider Web Analysis: Johnson and Johnson
9.4.5. Spider Web Analysis: Merck
9.4.6. Spider Web Analysis: Novartis
9.4.7. Spider Web Analysis: Novo Nordisk
9.4.8. Spider Web Analysis: Pfizer
9.4.9. Spider Web Analysis: Roche
9.4.10. Spider Web Analysis: Takeda Pharmaceutical

9.5. Concluding Remarks

10. RECENT DEVELOPMENTS AND INITIATIVES
10.1. Chapter Overview
10.2. Partnership Models
10.3. Live Biotherapeutic Products and Microbiome: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Organization
10.3.5. Analysis by Type of Partnership and Type of Organization
10.3.6. Analysis by Target Therapeutic Area
10.3.7. Most Active Players: Analysis by Number of Partnerships
10.3.8. Analysis by Region
10.3.8.1. Intracontinental and Intercontinental Agreements
10.3.8.2. Local and International Agreements

10.3.9. Cumulative Year-wise Trend of Merger / Acquisition
10.3.10. Analysis by Type of Acquisition
10.3.11. Analysis by Key Value Drivers
10.3.12. Analysis by Year of Acquisition and Key Value Drivers

10.4. Live Biotherapeutic Products and Microbiome: Recent Expansions
10.4.1. Analysis by Year of Expansion
10.4.2. Analysis by Purpose of Expansion
10.4.3. Analysis by Year and Purpose of Expansion
10.4.4. Analysis by Scale of Operation
10.4.5. Analysis by Purpose of Expansion and Scale of Operation
10.4.6. Analysis by Region
10.4.6.1. Analysis by Location of Manufacturing Facility (Continent-wise)
10.4.6.2. Analysis by Location of Manufacturing Facility (Country-wise)
10.4.7. Analysis by Purpose of Expansion and Location of Manufacturing Facility

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Live Biotherapeutic Products and Microbiome: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Status
11.3.3. Analysis by Trial Phase
11.3.4. Analysis by Trial Registration Year and Trial Recruitment Status
11.3.5. Analysis by Trial Registration Year and Enrolled Patient Population
11.3.6. Analysis by Study Design
11.3.7. Most Active Players: Analysis by Number of Registered Trials
11.3.7. Emerging Focus Area
11.3.9. Analysis by Therapeutic Area
11.3.10. Geographical Analysis by Number of Registered Trials
11.3.11. Geographical Analysis by Enrolled Patient Population

12. CAPACITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology

12.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Global Production Capacity
12.3.1. Analysis by Company Size
12.3.2. Analysis by Scale of Operation
12.3.3. Analysis by Region
12.3.3.1. Capacity Analysis: North America
12.3.3.2. Capacity Analysis: Europe
12.3.3.3. Capacity Analysis: Asia-Pacific
12.4. Concluding Remarks

13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing
13.4. Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing
13.4.1. Geographical Analysis of Clinical Demand
13.4.1.1. Clinical Demand in North America
13.4.1.2. Clinical Demand in Europe
13.4.1.3. Clinical Demand in Asia-Pacific and Rest of the World

13.4.2. Analysis of Clinical Demand by Trial Phase
13.5. Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing
13.6. Concluding Remarks

14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
14.1. Chapter Overview
14.2. Assumptions and Key Parameter
14.3. Live Biotherapeutic Products and Microbiome Contract Manufacturers: Make versus Buy Decision Making
14.3.1. Scenario 1
14.3.2. Scenario 2
14.3.3. Scenario 3
14.3.4. Scenario 4
14.4. Concluding Remarks

15. CASE STUDY: LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CONTRACT RESEARCH ORGANIZATIONS (CROs) AND DIETARY SUPPLEMENT MANUFACTURERS
15.1. Chapter Overview
15.2. Live Biotherapeutic Products and Microbiome CROs: Overall Market Landscape
15.2.1. Analysis by Year of Establishment
15.2.2. Analysis by Company Size
15.2.3. Analysis by Location of Headquarters

15.3. Microbiome Dietary Supplement Manufacturers: Overall Market Landscape
15.3.1. Analysis by Year of Establishment
15.3.2. Analysis by Company Size
15.3.3. Analysis by Location of Headquarters

16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology
16.3. Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035

16.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Type of Product Manufactured
16.4.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035
16.4.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035

16.5. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Type of Formulation
16.5.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Solid Formulations, 2022-2035
16.5.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Oral Liquids, 2022-2035
16.5.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035
16.5.4. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035

16.6. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Scale of Operation
16.6.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035
16.6.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035

16.7. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Analysis by Company Size
16.7.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035
16.7.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035
16.7.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035

16.8. Microbiome Contract Manufacturing Market: Analysis by Geography
16.8.1. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2022-2035
16.8.2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2022-2035
16.8.3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Asia-Pacific and Rest of the World, 2022-2035
16.9. Concluding Remarks

17. CONCLUSION
17.1. Chapter Overview

18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Traci Kyes, Vice President of Commercial Operations, Arranta Bio
18.2.1. Arranta Bio: Key Highlights
18.2.2. Interview Transcript

18.2. JP Benya, Vice President, Business Development, Assembly Biosciences
18.2.1. Assembly Biosciences: Key Highlights
18.2.2. Interview Transcript

18.3. Assaf Oron, Chief Business Officer, BiomX
18.3.1. BiomX: Key Highlights
18.3.2. Interview Transcript

18.4. Alexander Lin, Associate General Manager, Chung Mei Pharmaceutical
18.4.1. Chung Mei Pharmaceutical: Key Highlights
18.4.2. Interview Transcript

18.5. Debbie Pinkston, Vice President, Sales and Business Development, List
18.5.1. List Biological Laboratories: Key Highlights
18.5.2. Interview Transcript

18.6. Max Rosetto, Head of Business Development, Luina Bio
18.6.1. Luina Bio: Key Highlights
18.6.2. Interview Transcript

18.7. Gaurav Kaushik, Managing Director and Chief Executive Officer, Meteoric
18.7.1. Meteoric Biopharmaceuticals: Key Highlights
18.7.2. Interview Transcript

18.8. Veronika Oudova, Co-founder and Chief Executive Officer, S-Biomedic
18.8.1. S-Biomedic: Key Highlights
18.8.2. Interview Transcript 

18.9. Nikole Kimes, Founder and Chief Executive Officer, Siolta Therapeutics
18.9.1. Siolta Therapeutics: Key Highlights
18.9.2. Interview Transcript

18.10. Alexander Segal, Vice President, Business Development, Universal
18.10.1. Universal Stabilization Technologies: Key Highlights
18.10.2. Interview Transcript

18.11. Rob Van Dijk, Business Development Manager, Wacker Biotech
18.11.1. Wacker Biotech: Key Highlights
18.11.2. Interview Transcript

19. APPENDIX I: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Recent Development and Initiatives
Figure 2.3 Executive Summary: Capacity Analysis
Figure 2.4 Executive Summary: Demand Analysis
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Key Benefits of Human Microbiota
Figure 3.2 Factors Affecting the Gut Flora
Figure 3.3 Human Microbiome Project: Key Achievements
Figure 3.4 Microbiome Therapies: Design Approaches
Figure 3.5 Types of Microbiome Therapies
Figure 3.6 Probiotic Drugs: Overview of Beneficial Bacterial Strains
Figure 3.7 Microbiome Therapies: Potential Application Areas
Figure 3.8 Key Steps Involved in Microbiome Therapeutics Supply Chain
Figure 3.9 Key Steps Involved in Microbiome Therapeutics Manufacturing
Figure 3.10 Key Challenges in Manufacturing of Microbiome Therapeutics
Figure 3.11 Key Strategies to Increase Efficiency in Manufacturing Microbiome Therapeutics
Figure 3.12 Microbiome Manufacturing Industry Survey: Distribution by Respondent Particulars
Figure 3.13 Microbiome Manufacturing Industry Survey: Distribution by Manufacturing Preference
Figure 4.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Figure 4.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Figure 4.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 4.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Figure 4.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Figure 4.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Primary Packaging Used
Figure 4.9 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation and Type of Primary Packaging Used
Figure 4.10 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation
Figure 4.11 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation and Location of Headquarters
Figure 4.12 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Service(s) Offered
Figure 4.13 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Figure 4.14 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.15 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Year of Establishment
Figure 4.16 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Company Size
Figure 4.17 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Headquarters
Figure 4.18 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Scale of Operation
Figure 4.19 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 5.1 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
Figure 5.2 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
Figure 5.3 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
Figure 6.1 Company Competitiveness: Distribution of Players based in North America
Figure 6.2 Company Competitiveness: Distribution of Players based in Europe
Figure 6.3 Company Competitiveness: Distribution of Players based in Asia-Pacific
Figure 6.4 Company Competitiveness: Distribution of Top 10 Players (Wind Rose Representation)
Figure 7.1 Capsugel: Service Portfolio
Figure 7.2 Jeneil Biotech: Service Portfolio
Figure 7.3 UAS Labs: Service Portfolio
Figure 7.4 Biose: Service Portfolio
Figure 7.5 Cerbios-Pharma: Service Portfolio
Figure 7.6 Inpac Probiotics: Service Portfolio
Figure 7.7 NIZO: Service Portfolio
Figure 7.8 Winclove Probiotics: Service Portfolio
Figure 7.9 BJP Laboratories: Service Portfolio
Figure 9.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies (Heat Map Representation)
Figure 9.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 9.3 Big Pharma Players: Distribution by Phase of Development
Figure 9.4 Big Pharma Players: Distribution by Type of Therapy
Figure 9.5 Big Pharma Players: Distribution by Type of Drug Molecule
Figure 9.6 Big Pharma Players: Distribution by Target Therapeutic Areas
Figure 9.7 Spider Web Analysis: AbbVie
Figure 9.8 Spider Web Analysis: AstraZeneca
Figure 9.9 Spider Web Analysis: BMS
Figure 9.10 Spider Web Analysis: Johnson and Johnson
Figure 9.11 Spider Web Analysis: Merck
Figure 9.12 Spider Web Analysis: Novartis
Figure 9.13 Spider Web Analysis: Novo Nordisk
Figure 9.14 Spider Web Analysis: Pfizer
Figure 9.15 Spider Web Analysis: Roche
Figure 9.16 Spider Web Analysis: Takeda Pharmaceutical
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Organization
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Organization
Figure 10.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.7 Most Active Players: Distribution by Number of Partnerships
Figure 10.8 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.9 Partnerships and Collaborations: Local and International Agreements
Figure 10.10 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
Figure 10.11 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 10.12 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 10.13 Recent Expansions: Distribution by Year of Expansion
Figure 10.14 Recent Expansions: Distribution by Purpose of Expansion
Figure 10.15 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 10.16 Recent Expansions: Distribution by Scale of Operation
Figure 10.17 Recent Expansions: Distribution by Purpose of Expansion and Scale of Operation
Figure 10.18 Recent Expansions: Distribution by Location of Manufacturing Facility (Continent-wise)
Figure 10.19 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 10.20 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Figure 11.1 Clinical Trial Analysis: Scope and Methodology
Figure 11.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2021
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2013-2021
Figure 11.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2021
Figure 11.7 Clinical Trial Analysis: Distribution by Study Design
Figure 11.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.9 Most Active Players: Distribution by Number of Registered Trials
Figure 11.10 Clinical Trial Analysis: Emerging Focus Areas
Figure 11.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 11.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 12.1 Capacity Analysis: Distribution by Company Size
Figure 12.2 Capacity Analysis: Distribution by Scale of Manufacturing
Figure 12.3 Capacity Analysis: Distribution by Region
Figure 12.4 Capacity Analysis: Microbiome Contract Manufacturing Capacity in North America
Figure 12.5 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Europe
Figure 12.6 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Asia-Pacific
Figure 13.1 Global Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Patients)
Figure 13.2 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Trials Conducted)
Figure 13.3 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Enrolled Patients)
Figure 13.4 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Geography
Figure 13.5 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in North America, 2022-2031 (Number of Enrolled Patients)
Figure 13.6 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Europe, 2022-2031 (Number of Enrolled Patients)
Figure 13.7 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2022-2031 (Number of Enrolled Patients)
Figure 13.8 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Trial Phase, 2022-2031 (Number of Enrolled Patients)
Figure 13.9 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Target Patient Population)
Figure 14.1 Make versus Buy Decision Making Framework
Figure 14.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 15.1 Live Biotherapeutic Products and Microbiome CROs: Distribution by Year of Establishment
Figure 15.2 Live Biotherapeutic Products and Microbiome CROs: Distribution by CompanySize
Figure 15.3 Live Biotherapeutic Products and Microbiome CROs: Distribution by Location of Headquarters
Figure 15.4 Microbiome Dietary Supplement Manufacturers: Distribution by Year of Establishment
Figure 15.5 Microbiome Dietary Supplement Manufacturers: Distribution by CompanySize
Figure 15.6 Microbiome Dietary Supplement Manufacturers: Distribution by Location of Headquarters
Figure 16.1 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035 (USD Million)
Figure 16.2 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market:Distribution by Type of Product Manufactured.
Figure 16.3 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035 (USD Million)
Figure 16.4 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035 (USD Million)
Figure 16.5 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market:Distribution by Type of Formulation
Figure 16.6 Live Biotherapeutic Products and Microbiome Contract Manufacturing Marketfor Solid Formulations, 2022-2035 (USD Million)
Figure 16.7 Live Biotherapeutic Products and Microbiome Contract Manufacturing Marketfor Oral Liquids, 2022-2035 (USD Million)
Figure 16.8 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035 (USD Million)
Figure 16.9 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035 (USD Million)
Figure 16.10 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market:Distribution by Scale of Operation 
Figure 16.11 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035 (USD Million)
Figure 16.12 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035 (USD Million)
Figure 16.13 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size
Figure 16.14 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035 (USD Million)
Figure 16.15 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035 (USD Million)
Figure 16.16 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035 (USD Million)
Figure 16.17 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Geography
Figure 16.18 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2022-2035 (USD Million)
Figure 16.19 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2022-2035 (USD Million)
Figure 16.20 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 17.1 Concluding Remarks: Overall Market Landscape
Figure 17.2 Concluding Remarks: Recent Development and Initiatives
Figure 17.3 Concluding Remarks: Capacity Analysis
Figure 17.4 Concluding Remarks: Demand Analysis
Figure 17.5 Concluding Remarks: Market Forecast and Opportunity Analysis
Figure 17.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Different Types of Microbiota in the Gastrointestinal Tract
Table 3.2 Various Food Items Containing Prebiotics
Table 3.3 Harvey Ball Analysis: Comparison of Key Factors for the Selection of CMOs
Table 4.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: MarketLandscape
Table 4.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers:Information on Type of Product Manufactured
Table 4.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers:Information on Type of Formulation
Table 4.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers:Information on Type of Primary Packaging Used
Table 4.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers:Information on Type of Fermentation
Table 4.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers:Information on Type of Service(s) Offered
Table 4.7 Live Biotherapeutic Products and Contract Manufacturers: Information onManufacturing Facilities
Table 4.8 Live Biotherapeutic Products and Microbiome In-House Manufacturers: MarketLandscape
Table 7.1 Capsugel: Company Overview
Table 7.2 Jeneil Biotech: Company Overview
Table 7.3 UAS Labs: Company Overview
Table 7.4 UAS Labs: Recent Developments and Future Outlook
Table 7.5 Biose: Company Overview
Table 7.6 Biose: Recent Developments and Future Outlook
Table 7.7 Cerbios-Pharma: Company Overview
Table 7.8 Inpac Probiotics: Company Overview
Table 7.9 NIZO: Company Overview
Table 7.10 Winclove Probiotics: Company Overview
Table 7.11 Winclove Probiotics: Recent Developments and Future Outlook
Table 7.12 BJP Laboratories: Company Overview
Table 8.1 Likely Partners for Live Biotherapeutic Products and Microbiome ContractManufacturers in North America
Table 8.2 Likely Partners for Live Biotherapeutic Products and Microbiome ContractManufacturers in Europe
Table 8.3 Likely Partners for Live Biotherapeutic Products and Microbiome ContractManufacturers in Asia-Pacific
Table 10.1 Live Biotherapeutic Products and Microbiome: List of Partnerships andCollaborations, 2016-2021
Table 10.2 Live Biotherapeutic Products and Microbiome Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2021
Table 10.3 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2021
Table 10.4 Live Biotherapeutic Products and Microbiome: List of Recent Expansions, 2019-2020
Table 12.1 Capacity Analysis: Average Capacity per Category
Table 12.2 Capacity Analysis: Global Contract Microbiome Manufacturing Capacity
Table 13.1 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Information on Number of Enrolled Patients by Trial Phase
Table 13.2 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Information on Phase III Microbiome-based Live Biotherapeutic Products
Table 16.1 Live Biotherapeutic Products and Microbiome CROs
Table 16.2 Microbiome Dietary Supplement Manufacturers
Table 19.1 Arranta Bio: Key Highlights
Table 19.2 Assembly Biosciences: Key Highlights
Table 19.3 BiomX: Key Highlights
Table 19.4 Chung Mei Pharmaceutical: Key Highlights
Table 19.5 List Biological Laboratories: Key Highlights
Table 19.6 Luina Bio: Key Highlights
Table 19.7 Meteoric Biopharmaceuticals: Key Highlights
Table 19.8 S-Biomedic: Key Highlights
Table 19.9 Siolta Therapeutics: Key Highlights
Table 19.10 Universal Stabilization Technologies: Key Highlights
Table 19.11 Wacker Biotech: Key Highlights
Table 20.1 Microbiome Manufacturing Industry Survey: Distribution by Respondent Particulars
Table 20.2 Microbiome Manufacturing Industry Survey: Distribution by Manufacturing Preference
Table 20.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Table 20.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Table 20.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Table 20.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Table 20.7 Microbiome Therapeutics Contract Manufacturers: Distribution by Type of Product Manufactured
Table 20.8 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Table 20.9 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Table 20.10 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Primary Packaging Used
Table 20.11 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation and Type of Primary Packaging Used
Table 20.12 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation
Table 20.13 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Fermentation and Location of Headquarters
Table 20.14 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Service(s) Offered
Table 20.15 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Table 20.16 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 20.17 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Year of Establishment
Table 20.18 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Company Size
Table 20.19 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Headquarters
Table 20.20 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Scale of Operation
Table 20.21 Live Biotherapeutic Products and Microbiome In-House Manufacturers: Distribution by Location of Manufacturing Facilities
Table 20.22 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in North America
Table 20.23 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Europe
Table 20.24 Regional Capability Analysis: Live Biotherapeutic Products and Microbiome Contract Manufacturers in Asia-Pacific
Table 20.25 Partnerships and Collaborations: Distribution by Year of Partnership
Table 20.26 Partnerships and Collaborations: Distribution by Type of Partnership
Table 20.27 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 20.28 Partnerships and Collaborations: Distribution by Type of Organization
Table 20.29 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Organization
Table 20.30 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 20.31 Most Active Players: Distribution by Number of Partnerships
Table 20.32 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 20.33 Partnerships and Collaborations: Local and International Agreements
Table 20.34 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
Table 20.35 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 20.36 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 20.37 Recent Expansions: Distribution by Year of Expansion
Table 20.38 Recent Expansions: Distribution by Purpose of Expansion
Table 20.39 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 20.40 Recent Expansions: Distribution by Scale of Operation
Table 20.41 Recent Expansions: Distribution by Purpose of Expansion and Scale of Operation
Table 20.42 Recent Expansions: Distribution by Location of Manufacturing Facility (Continent-wise)
Table 20.43 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Table 20.44 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
Table 20.45 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2021
Table 20.46 Clinical Trial Analysis: Distribution by Trial Status
Table 20.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 20.48 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status, Pre-2013-2021
Table 20.49 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2021
Table 20.50 Clinical Trial Analysis: Distribution by Study Design
Table 20.51 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 20.52 Most Active Players: Distribution by Number of Registered Trials
Table 20.53 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 20.54 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 20.55 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 20.56 Capacity Analysis: Distribution by Company Size
Table 20.57 Capacity Analysis: Distribution by Scale of Manufacturing
Table 20.58 Capacity Analysis: Distribution by Region
Table 20.59 Capacity Analysis: Microbiome Contract Manufacturing Capacity in North America
Table 20.60 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Europe
Table 20.61 Capacity Analysis: Microbiome Contract Manufacturing Capacity in Asia-Pacific
Table 20.62 Global Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Patients)
Table 20.63 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Trials Conducted)
Table 20.64 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Enrolled Patients)
Table 20.65 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Geography
Table 20.66 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in North America, 2022-2031 (Number of Enrolled Patients)
Table 20.67 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Europe, 2022-2031 (Number of Enrolled Patients)
Table 20.68 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing in Asia-Pacific and Rest of the World, 2022-2031 (Number of Enrolled Patients)
Table 20.69 Global Clinical Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing: Distribution by Trial Phase, 2022-2031 (Number of Enrolled Patients)
Table 20.70 Global Commercial Demand for Live Biotherapeutic Products and Microbiome Contract Manufacturing, 2022-2031 (Number of Target Patient Population)
Table 20.71 Live Biotherapeutic Products and Microbiome CROs: Distribution by Year of Establishment
Table 20.72 Live Biotherapeutic Products and Microbiome CROs: Distribution by CompanySize
Table 20.73 Live Biotherapeutic Products and Microbiome CROs: Distribution by Location of Headquarters
Table 20.74 Microbiome Dietary Supplement Manufacturers: Distribution by Year of Establishment
Table 20.75 Microbiome Dietary Supplement Manufacturers: Distribution by CompanySize
Table 20.76 Microbiome Dietary Supplement Manufacturers: Distribution by Location of Headquarters
Table 20.77 Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2022-2035 (USD Million)
Table 20.78 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market:Distribution by Type of Product Manufactured.
Table 20.79 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for APIs, 2022-2035 (USD Million)
Table 20.80 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for FDFs, 2022-2035 (USD Million)
Table 20.81 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market:Distribution by Type of Formulation
Table 20.82 Live Biotherapeutic Products and Microbiome Contract Manufacturing Marketfor Solid Formulations, 2022-2035 (USD Million)
Table 20.83 Live Biotherapeutic Products and Microbiome Contract Manufacturing Marketfor Oral Liquids, 2022-2035 (USD Million)
Table 20.84 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Injectables, 2022-2035 (USD Million)
Table 20.85 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Others, 2022-2035 (USD Million)
Table 20.86 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market:Distribution by Scale of Operation 
Table 20.87 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Clinical Operations, 2022-2035 (USD Million)
Table 20.88 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Commercial Operations, 2022-2035 (USD Million)
Table 20.89 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Company Size
Table 20.90 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Small Companies, 2022-2035 (USD Million)
Table 20.91 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Mid-sized Companies, 2022-2035 (USD Million)
Table 20.92 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market for Large Companies, 2022-2035 (USD Million)
Table 20.93 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Distribution by Geography
Table 20.94 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in North America, 2022-2035 (USD Million)
Table 20.95 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market in Europe, 2022-2035 (USD Million)
Table 20.96 Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 4D Pharma
  2. AbbVie
  3. ABCO Laboratories
  4. ABH Pharma
  5. Adare Pharmaceuticals
  6. ADM Biopolis
  7. Advanced Enzymes
  8. Allianz Biosciences
  9. AmpliPhi Biosciences
  10. AOBiome Therapeutics
  11. Arena Pharmaceuticals
  12. Armata Pharmaceuticals
  13. Arranta Bio
  14. AsiaBiome
  15. Assembly Biosciences
  16. AstraZeneca
  17. Atlantic Essential Products
  18. Aumgene Biosciences
  19. Axial Therapeutics
  20. Azabu University
  21. Azitra
  22. BacThera
  23. Biena
  24. Bifodan
  25. BIOASTER
  26. BioCare
  27. Biocodex
  28. BioGaia
  29. Biomar Microbial Technologies
  30. Biomcare
  31. Bio-Me
  32. Biomica (a subsidary of Evogene)
  33. Biomillenia
  34. BiomX
  35. Biose
  36. Biosortia Pharmaceuticals
  37. BJP Laboratories
  38. Bloom Science
  39. Blue Turtle Bio
  40. Boehringer Ingelheim
  41. Bristol-Myers Squibb
  42. C3J Therapeutics
  43. Caelus Health
  44. Cambridge University Hospitals NHS Foundation Trust
  45. Cancer Research UK
  46. Capsugel
  47. Captozyme
  48. Cell Biotech
  49. Cerbios-Pharma
  50. CHAIN Biotechnology
  51. Charles River Laboratories
  52. Chr. Hansen
  53. Clinical Microbiomics
  54. ClostraBio
  55. Commense (a subsidiary of PureTech Health)
  56. CoreBiome
  57. CosmosID
  58. Crestovo
  59. Custom Probiotics
  60. Da Volterra
  61. Debiopharm
  62. Deerland Probiotics & Enzymes
  63. DermBiont
  64. Diversigen
  65. DuPont
  66. EirGenix
  67. Emerge Health
  68. EMF
  69. Emulate
  70. Enterin
  71. EnteroBiotix
  72. Enterome
  73. Evelo Biosciences
  74. Evologic Technologies
  75. EXDEN
  76. Exeliom Biosciences
  77. Exim Pharma
  78. Ferring Pharmaceuticals
  79. Finch Therapeutics
  80. FUJIFILM Diosynth Biotechnologies
  81. Ganeden Biotech
  82. GENIBIO (a subsidiary of the LARENA and GB ACTION)
  83. Genome & Company
  84. GI Innovation
  85. Gilead Sciences
  86. Ginkgo Bioworks
  87. Gustave Roussy
  88. Gusto Global
  89. Heidelberg University
  90. iCarbonX
  91. Igen BioLab Group
  92. ImmuneBiotech
  93. Immuron
  94. Infant Bacterial Therapeutics
  95. Inpac Probiotics
  96. Ion Labs
  97. Jeneil Biotech
  98. John Theurer Cancer Center
  99. Johnson & Johnson
  100. JW Nutritional
  101. Kaleido Biosciences
  102. Karolinska Institutet
  103. Karyotica Biologicals
  104. Kendy Pharma
  105. Kibow Biotech
  106. Lallemand
  107. Leadiant Biosciences
  108. Leiden University Medical Center
  109. List Biological Laboratories
  110. LNC Therapeutics
  111. Locus Biosciences
  112. Lonza
  113. LUCA Biologics
  114. Luina Bio
  115. MaaT Pharma
  116. Massachusetts General Hospital
  117. MatriSys Bioscience
  118. Mayo Clinic
  119. Medella Naturals
  120. Memorial Sloan Kettering Cancer Center
  121. Merck
  122. MeriCal
  123. MetaboGen
  124. Meteoric Biopharmaceuticals
  125. Microba Life Sciences
  126. Microbax
  127. Microbiome Insights
  128. MicrobiomeDx
  129. Microbiotica
  130. Microviable Therapeutics
  131. Mirna Therapeutics
  132. MRM Health
  133. MSD
  134. MyBiotics
  135. Naked Biome
  136. Nestlé Health Science
  137. New Bellus
  138. Nexbiome Therapeutics
  139. NIZO
  140. Norax Supplements
  141. North Zealand University Hospital
  142. Novartis
  143. Novo Nordisk
  144. NuBiyota
  145. NutraScience Labs
  146. NYU Grossman School of Medicine
  147. Osel
  148. OxThera
  149. Parker Institute for Cancer Immunotherapy
  150. Parkinson’s Institute and Clinical Center
  151. Pfizer
  152. Phi Therapeutics
  153. Phylagen
  154. Precigen ActoBio
  155. Probi
  156. ProbioFerm
  157. Probiotical
  158. Probiotics Australia
  159. ProDigest
  160. Protexin
  161. Qu Biologics
  162. Quay Pharma
  163. Quorum Innovations
  164. Rebiotix
  165. The Research Institute of St
  166. Resphera Biosciences
  167. RIKEN
  168. Rise Therapeutics
  169. Roche
  170. RondinX
  171. Roswell Park Comprehensive Cancer Center
  172. Sabinsa
  173. Sacco
  174. S-Biomedic
  175. SciBac
  176. Scioto Biosciences
  177. Second Genome
  178. Seres Therapeutics
  179. SeylanMED
  180. SFA Therapeutics
  181. Siolta Therapeutics
  182. Sirio Pharma
  183. SNIPR Biome
  184. Specialty Enzymes & Probiotics
  185. Stanford Cancer Institute
  186. Stanford University School of Medicine
  187. Stellate Therapeutics
  188. Symberix
  189. Syngen Biotech
  190. Synlogic
  191. Synthetic Biologics
  192. Takeda Pharmaceutical
  193. The Medical University of Graz
  194. The University of Texas MD Anderson Cancer Center
  195. The University of Tokyo
  196. Trayer Biotherapeutics
  197. UAS Labs
  198. Unique Biotech
  199. University of Adelaide
  200. University of Nottingham
  201. University of Oxford
  202. University of Pennsylvania
  203. University of Reading
  204. Vaiomer
  205. Vedanta Biosciences
  206. VITA-gen Laboratories
  207. Vitakem
  208. Wacker Biotech
  209. Washington University School of Medicine
  210. White Rock Capital Partners
  211. Winclove Probiotics
  212. Xycrobe Therapeutics (a subsidiary of Crown Laboratories)
  213. Yakult Honsha
  214. Zeta Farmaceutici

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com